Home News Publication in Journal of Neurosurgery demonstrates the benefits of CLS’ technology

Publication in Journal of Neurosurgery demonstrates the benefits of CLS’ technology


Publication in Journal of Neurosurgery demonstrates the benefits of CLS’ technology

19 March, 2024

A scientific article published in the Journal of Neurosurgery demonstrates the advantages of Clinical Laserthermia System’s MRI-guided laser ablation systems for neurosurgery. The results are important for the commercialisation of the system and the clinical application in brain tumour or epilepsy patients.

Clinical Laserthermia Systems (CLS) develops and sells the TRANBERG Thermal Therapy System, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment in urology, oncology and neurosurgery. The image-guided laser treatment can be used for the treatment of various conditions, such as brain tumours, drug-resistant epilepsy and prostate cancer.

Scientific article published

On March 11, CLS announced that a scientific article with the title “Preclinical assessment of a non-cooled MR thermometry-based neurosurgical laser therapy system” had been published in the well renowned Journal of Neurosurgery.

The results in the article stem from a study conducted by CLS and the company’s partner ClearPoint Neuro, with neurosurgeon Dr John Rolston, MD, PhD as the principal investigator. CLS TRANBERG non-cooled laser applicators were used in an animal model to demonstrate the safety, accuracy, and efficacy of the laser treatment system for neurosurgery. The laser light induced thermal damage in the target tissue, resulting in coagulative necrosis and cell death.

Thermoguide guides through temperature map

The company’s Thermoguide software for thermometry protects healthy tissue, and it also obtains accurate temperature maps of the brain tissue in near real time. The software provides color-coded thermal damage thresholds that predict the expected tissue damage, and clearly delineated safety margins for eloquent brain structures.

Limited market launch and study at SUS

The study results helped obtain 510(k) clearance from the FDA in the US, where a limited market release is underway at selected academic medical centres. The company’s partner ClearPoint Neuro is responsible for the commercialisation, using the brand name ClearPoint Prism.

In addition, a CLS-sponsored clinical study is currently underway at Skåne University Hospital (SUS) to investigate the effect of the laser ablation treatment in glioblastoma, which is an aggressive and difficult-to-treat form of cancer of the brain.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev